Healthcare provider profile · identity verified

Gerald A Valletta, MD

Internal Medicine · WATERBURY, CT · NPI 1417991688

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	350	56
Amlodipine Besylate	Amlodipine Besylate	246	42
Metoprolol Succinate	Metoprolol Succinate	195	32
Levothyroxine Sodium	Levothyroxine Sodium	187	36
Escitalopram Oxalate	Escitalopram Oxalate	170	22
Donepezil Hcl	Donepezil Hcl	166	26
Pantoprazole Sodium	Pantoprazole Sodium	156	24
Furosemide	Furosemide	147	26
Trazodone Hcl	Trazodone Hcl	140	31
Losartan Potassium	Losartan Potassium	137	22
Lisinopril	Lisinopril	133	22
Famotidine	Famotidine	113	16
Memantine Hcl	Memantine Hcl	97	17
Mirtazapine	Mirtazapine	88	15
Eliquis	Apixaban	85	20
Rosuvastatin Calcium	Rosuvastatin Calcium	85	15
Gabapentin	Gabapentin	77	11
Omeprazole	Omeprazole	68	14
Tamsulosin Hcl	Tamsulosin Hcl	62	11
Meloxicam	Meloxicam	53	12
Potassium Chloride	Potassium Chloride	52	suppressed
Sertraline Hcl	Sertraline Hcl	51	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	50	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	46	13
Torsemide	Torsemide	46	suppressed
Pravastatin Sodium	Pravastatin Sodium	45	suppressed
Spironolactone	Spironolactone	45	suppressed
Digoxin	Digoxin	43	suppressed
Finasteride	Finasteride	42	suppressed
Simvastatin	Simvastatin	42	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	41	suppressed
Duloxetine Hcl	Duloxetine Hcl	39	suppressed
Midodrine Hcl	Midodrine Hcl	39	suppressed
Allopurinol	Allopurinol	38	suppressed
Montelukast Sodium	Montelukast Sodium	38	suppressed
Clopidogrel	Clopidogrel Bisulfate	35	suppressed
Fluticasone Propionate	Fluticasone Propionate	35	11
Latanoprost	Latanoprost	35	suppressed
Rivastigmine	Rivastigmine	35	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	34	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	34	suppressed
Prednisone	Prednisone	32	suppressed
Risperidone	Risperidone	32	suppressed
Carvedilol	Carvedilol	31	suppressed
Ezetimibe	Ezetimibe	27	suppressed
Memantine Hcl Er	Memantine Hcl	27	suppressed
Olanzapine	Olanzapine	27	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	25	suppressed
Myrbetriq	Mirabegron	25	suppressed
Metformin Hcl	Metformin Hcl	24	suppressed
Bupropion Xl	Bupropion Hcl	22	suppressed
Folic Acid	Folic Acid	21	suppressed
Levetiracetam	Levetiracetam	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	suppressed
Loperamide	Loperamide Hcl	19	suppressed
Baclofen	Baclofen	18	suppressed
Buspirone Hcl	Buspirone Hcl	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Colestipol Hcl	Colestipol Hcl	18	suppressed
Methenamine Hippurate	Methenamine Hippurate	18	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	17	suppressed
Atenolol	Atenolol	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Eplerenone	Eplerenone	15	suppressed
Timolol Maleate	Timolol Maleate	15	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	14	suppressed
Januvia	Sitagliptin Phosphate	14	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	13	suppressed
Creon	Lipase/Protease/Amylase	13	suppressed
Enalapril Maleate	Enalapril Maleate	13	suppressed
Leflunomide	Leflunomide	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Colesevelam Hcl	Colesevelam Hcl	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	11	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	11	suppressed
Jardiance	Empagliflozin	11	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	11	suppressed
Solifenacin Succinate	Solifenacin Succinate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error